Uberto Pagotto, ESPE 2022: GLP-1 agonists and other emerging treatments of obesity

Glucagon-like peptide-1 agonists are a class of medications utilized in the treatment of type 2 diabetes and obesity. In this touchENDOCRINOLOGY interview, Prof. Uberto Pagotto (University of Bologna, Bologna, Italy) discusses the impact of glucagon-like peptide 1 agonists on obesity, what other emerging treatments in obesity appear promising. The future direction in obesity research is also discussed. 

The abstract entitled: ‘Novel Advances in Obesity‘ was presented at the European Society for Paediatric Endocrinology, 15-17 Sept, 2022.

Questions:

1. What has been the impact of glucagon-like peptide 1 agonists on weight management? (0:18)
2. What other emerging agents appear promising in the treatment of obesity? (4:00)
3. What will be the future directions of obesity research? (7:27)

Disclosures: Uberto Pagotto has received honorarium from Bruno Pharma.

Support: Interview supported by Touch Medical Media. Interview conducted by Shanice Allen.

Recorded as a highlight of ESPE 2022